Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs

Cancer

Volumn 118, Issue 3, 2012, Pages 698-710

  Wong, Alissa Michelle Go ^a   Kong, Kar Lok ^a   Tsang, Janice Wing Hang ^a   Kwong, Dora Lai Wan ^a   Guan, Xin Yuan ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

biological marker; Epstein Barr Virus; microRNAs; nasopharyngeal neoplasms; screening

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; ONCOMIR; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; UPREGULATION;

ADULT; AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84856211556     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26309     Document Type: Article

References (60)

1. Young LS, Murray PG,. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003; 22: 5108-5121.
2. Niedobitek G,. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol. 2000; 53: 248-254.
3. Cai X, Schafer A, Lu S, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2006; 2: e23.
4. Chen HL, Lung MM, Sham JS, et al. Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells. Virology. 1992; 191: 193-201.
5. Ventura A, Jacks T,. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136: 586-591.
6. Inui M, Martello G, Piccolo S,. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 4: 252-263.
7. Zhang B, Pan X, Cobb GP, Anderson TA,. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302: 1-12.
8. Cullen BR,. Viral and cellular messenger RNA targets of viral microRNAs. Nature. 2009; 457: 421-425.
9. Lagana A, Forte S, Russo F, et al. Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints. J RNAi Gene Silencing. 2010; 6: 379-385.
10. Veksler-Lublinsky I, Shemer-Avni Y, Kedem K, Ziv-Ukelson M,. Gene bi-targeting by viral and human miRNAs. BMC Bioinformatics. 2010; 11: 249.
11. Xia T, O'Hara A, Araujo I, et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res. 2008; 68: 1436-1442.
12. Choy EY, Siu KL, Kok KH, et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med. 2008; 205: 2551-2560.
13. Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009; 100: 1002-1011.
14. Zhu JY, Pfuhl T, Motsch N, et al. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol. 2009; 83: 3333-3341.
15. Cosmopoulos K, Pegtel M, Hawkins J, et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol. 2009; 83: 2357-2367.
16. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18: 997-1066.
17. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105: 10513-10518.
18. Hui AB, Cheung ST, Fong Y, et al. Characterization of a new EBV-associated nasopharyngeal carcinoma cell line. Cancer Genet Cytogenet. 1998; 101: 83-88.
19. Li HM, Man C, Jin Y, et al. Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int J Cancer. 2006; 119: 1567-1576.
20. Cheung ST, Huang DP, Hui ABY, et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer. 1999; 83: 121-126.
21. Tsang CM, Zhang G, Seto E, et al. Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization. Int J Cancer. 2010; 127: 1570-1583.
22. Yan GS, Ping TW, Yi Z, et al. An epithelial cell line established from poorly differentiated nasopharyngeal carcinoma [in Chinese]. Cancer. 1983; 2: 70-72.
23. Zhang H, Tsao SW, Jin C, et al. Sequential cytogenetic and molecular cytogenetic characterization of an SV40T-immortalized nasopharyngeal cell line transformed by Epstein-Barr virus latent membrane protein-1 gene. Cancer Genet Cytogenet. 2004; 150: 144-152.
24. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ,. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008; 36 (Database Issue): D154-D158.
25. Kroh EM, Parkin RK, Mitchell PS, Tewari M,. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 10: 298-301.
26. Brown BD, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol. 2007; 25: 1457-1467.
27. Lewis BP, Burge CB, Bartel DP,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-16.
28. Huang DW, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols. 2009; 4: 44-57.
29. Chen M, Lee H, Chang J, Chang C,. Expression of p53 protein and primary tumour volume in patients with nasopharyngeal carcinoma. J Otolaryngol. 2004; 33: 304-317.
30. Iizasa H, Wulff BE, Alla NR, et al. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem. 2010; 285: 33358-33370.
31. Chen YJ, Ko JY, Chen PJ, et al. Chromosomal aberrations in nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Genes Chromosomes Cancer. 1999; 25: 169-175.
32. Rasmussen KD, Simmini S, Abreu-Goodger C, et al. The miR-144/451 locus is required for erythroid homeostasis. J Exp Med. 2010; 207: 1351-1358.
33. Sangokoya C, Telen MJ, Chi JT,. MicroRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood. 2010; 116: 4338-4348.
34. Bandres E, Bitarte N, Arias F, et al. MicroRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009; 15: 2281-2290.
35. Pigati L, Yaddanapudi SCS, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010; 5: e13515.
36. Rowe M, Finke J, Szigeti R, Klein G,. Characterization of the serological response in man to the latent membrane protein and the 6 nuclear antigens encoded by Epstein-Barr virus. J Gen Virol. 1988; 69 (pt 6): 1217-1228.
37. Miller G, Grogan E, Fischer DK, et al. Antibody responses to 2 Epstein-Barr virus nuclear antigens defined by gene transfer. N Engl J Med. 1985; 312: 750-755.
38. Cheng YC, Chen JY, Glaser R, Henle W,. Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 1980; 77: 6162-6165.
39. Liu MY, Chou WH, Nutter L, Hsu MM, Chen JY, Yang CS,. Antibody against Epstein-Barr virus DNA polymerase activity in sera of patients with nasopharyngeal carcinoma. J Med Virol. 1989; 28: 101-105.
40. Littler E, Baylis SA, Zeng Y, Conway MJ, Mackett M, Arrand JR,. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet. 1991; 337: 685-689.
41. Fones-Tan A, Chan SH, Tsao SY, et al. Enzyme-linked immunosorbent assay (ELISA) for IgA and IgG antibodies to Epstein-Barr-virus ribonucleotide reductase in patients with nasopharyngeal carcinoma. Int J Cancer. 1994; 59: 739-742.
42. Ng WT, Choi CW, Lee MC, et al. Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer. 2010; 9: 221-228.
43. Leung SF, Tam JS, Chan AT, et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem. 2004; 50: 339-345.
44. Yang X, Goldstein AM, Chen CJ, et al. Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer. 2006; 118: 780-784.
45. Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004; 100: 1162-1170.
46. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer. 1999; 84: 442-448.
47. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM,. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol. 2000; 111: 239-246.
48. Lo AK, To KF, Lo KW, et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A. 2007; 104: 16164-16169.
49. Chou J, Lin YC, Kim J, et al. Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck. 2008; 30: 946-963.
50. Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 2005; 114: 242-248.
51. Lin YC, You L, Xu Z, et al. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun. 2006; 341: 635-640.
52. Huang GW, Mo WN, Kuang GQ, et al. Expression of p16, nm23-H1, E-cadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope. 2001; 111: 1465-1471.
53. Zheng Z, Pan J, Chu B, et al. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol. 1999; 30: 458-466.
54. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N,. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008; 455: 58-63.
55. Huntzinger E, Izaurralde E,. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011; 12: 99-110.
56. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP,. The impact of microRNAs on protein output. Nature. 2008; 455: 64-71.
57. Hsieh JC, Kodjabachian L, Rebbert ML, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature. 1999; 398: 431-436.
58. Ishitani T, Ninomiya-Tsuji J, Nagai S, et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature. 1999; 399: 798-802.
59. Aoki K, Taketo MM,. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci. 2007; 120 (pt 19): 3327-3335.
60. Stern-Ginossar N, Elefant N, Zimmermann A, et al. Host immune system gene targeting by a viral miRNA. Science. 2007; 317: 376-381.